Choose Your Country or Region

MCM2 (J16L17) Rabbit mAb

Catalog No.: F3772

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:1000- 1:10000 IHC1:200 IF1:1000

Application
WB, IHC, IF, FCM

Reactivity
Human, Mouse, Rat

Source
Rabbit

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
102 kDa 125 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Datasheet & SDS

Biological Description

Specificity
MCM2 (J16L17) Rabbit mAb detects endogenous levels of total MCM2 (J16L17) protein.

Clone
J16L17

Synonym(s)
BM28, CCNL1, CDCL1, KIAA0030, MCM2, DNA replication licensing factor MCM2, Minichromosome maintenance protein 2 homolog, Nuclear protein BM28.

Background
Minichromosome maintenance proteins (MCMs) are key players in the initiation of DNA replication and are essential for preserving genomic stability. Six conserved subunits—MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7—assemble into a hexameric, ring-shaped complex that functions as a DNA helicase to unwind the double-stranded DNA. Disruption in the expression or activation of the MCM2–7 complex can hinder DNA replication, promote genomic instability, and is strongly linked to tumor development and cancer progression. Among them, MCM2 plays a particularly critical role in regulating DNA replication. Its overexpression is observed in various cancer types, and its dysfunction is associated with tumor progression and poor patient outcomes. Due to this, MCM2 is regarded as a highly sensitive biomarker for cancer diagnosis, prognosis, and predicting chemotherapy responsiveness. The MCM2 gene—formerly referred to as BM28 or CDCL1—is located on chromosome 3q21 and consists of 17 exons. Inhibition of MCM2 has demonstrated anti-tumor effects, suggesting it could be a promising therapeutic target. Moreover, because MCM2 deficiency often leads to DNA replication stress, which can enhance anti-tumor immune responses, targeting MCM2 may also serve to boost the efficacy of cancer immunotherapy.

Background

Minichromosome maintenance proteins (MCMs) are key players in the initiation of DNA replication and are essential for preserving genomic stability. Six conserved subunits—MCM2, MCM3, MCM4, MCM5, MCM6, and MCM7—assemble into a hexameric, ring-shaped complex that functions as a DNA helicase to unwind the double-stranded DNA. Disruption in the expression or activation of the MCM2–7 complex can hinder DNA replication, promote genomic instability, and is strongly linked to tumor development and cancer progression. Among them, MCM2 plays a particularly critical role in regulating DNA replication. Its overexpression is observed in various cancer types, and its dysfunction is associated with tumor progression and poor patient outcomes. Due to this, MCM2 is regarded as a highly sensitive biomarker for cancer diagnosis, prognosis, and predicting chemotherapy responsiveness. The MCM2 gene—formerly referred to as BM28 or CDCL1—is located on chromosome 3q21 and consists of 17 exons. Inhibition of MCM2 has demonstrated anti-tumor effects, suggesting it could be a promising therapeutic target. Moreover, because MCM2 deficiency often leads to DNA replication stress, which can enhance anti-tumor immune responses, targeting MCM2 may also serve to boost the efficacy of cancer immunotherapy.

References
https://pubmed.ncbi.nlm.nih.gov/36303105/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%